In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Axsome Therapeutics Inc’s stock clocked out at $112.92, up 5.11% from its previous closing price of $107.43. In other words, the price has increased by $5.11 from its previous closing price. On the day, 0.83 million shares were traded. AXSM stock price reached its highest trading level at $113.32 during the session, while it also had its lowest trading level at $107.995.
Ratios:
To gain a deeper understanding of AXSM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.37 and its Current Ratio is at 2.44. In the meantime, Its Debt-to-Equity ratio is 2.07 whereas as Long-Term Debt/Eq ratio is at 2.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on December 31, 2024, Reiterated its Outperform rating but revised its target price to $122 from $124 previously.
On September 03, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $140.
BofA Securities Upgraded its Neutral to Buy on August 06, 2024, whereas the target price for the stock was revised from $95 to $106.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 11 ’24 when Saad Mark E sold 11,016 shares for $91.31 per share. The transaction valued at 1,005,871 led to the insider holds 10,002 shares of the business.
Saad Mark E bought 11,016 shares of AXSM for $1,005,843 on Sep 11 ’24. On Aug 09 ’24, another insider, Jacobson Mark L., who serves as the Chief Operating Officer of the company, sold 47,739 shares for $84.26 each. As a result, the insider received 4,022,488 and left with 5,783 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 5472374272 and an Enterprise Value of 5337330688. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.17 while its Price-to-Book (P/B) ratio in mrq is 58.88. Its current Enterprise Value per Revenue stands at 15.77 whereas that against EBITDA is -21.819.
Stock Price History:
The Beta on a monthly basis for AXSM is 1.03, which has changed by 0.14262927 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, AXSM has reached a high of $111.51, while it has fallen to a 52-week low of $64.11. The 50-Day Moving Average of the stock is 19.00%, while the 200-Day Moving Average is calculated to be 30.44%.
Shares Statistics:
It appears that AXSM traded 767.87K shares on average per day over the past three months and 969940 shares per day over the past ten days. A total of 48.44M shares are outstanding, with a floating share count of 39.60M. Insiders hold about 18.28% of the company’s shares, while institutions hold 79.74% stake in the company. Shares short for AXSM as of 1736899200 were 5752862 with a Short Ratio of 7.49, compared to 1734048000 on 6516027. Therefore, it implies a Short% of Shares Outstanding of 5752862 and a Short% of Float of 14.220000999999998.
Earnings Estimates
The company has 10.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.81 and low estimates of -$1.3.
Analysts are recommending an EPS of between -$3.66 and -$5.77 for the fiscal current year, implying an average EPS of -$5.24. EPS for the following year is -$1.77, with 11.0 analysts recommending between $2.99 and -$4.3.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $118.42M. It ranges from a high estimate of $123.21M to a low estimate of $113.9M. As of the current estimate, Axsome Therapeutics Inc’s year-ago sales were $71.53MFor the next quarter, 14 analysts are estimating revenue of $122.66M. There is a high estimate of $130.66M for the next quarter, whereas the lowest estimate is $105.25M.
A total of 16 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $390.13M, while the lowest revenue estimate was $380.83M, resulting in an average revenue estimate of $385.53M. In the same quarter a year ago, actual revenue was $270.6MBased on 16 analysts’ estimates, the company’s revenue will be $637.07M in the next fiscal year. The high estimate is $771.91M and the low estimate is $545M.
